NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
Updated: Sep 27, 2022
The NIMBUS trial
The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
Compare the Efficacy and Safety of Pomalidomide With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in relapsed MM and Companion Study (NIMBUS)
ClinicalTrials.gov Identifier: NCT01311687
Official Title: A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Click here to see details on ClinicalTrials.gov
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
PMID: 24007748; Lancet Oncol; Oct 2013
Click here to see details.
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
PMID: 27173785; Leuk Lymphoma; Dec 2016
Click here to see details